VanEck Rare Earth/Strategic Metals vs Tempus AI — how do they compare? VanEck Rare Earth/Strategic Metals trades at $60.97 (market cap $1.79B), while Tempus AI trades at $70 (market cap $12.77B). The key difference: Tempus AI is far larger — about 7.1× VanEck Rare Earth/Strategic Metals's market cap, and Tempus AI is trading nearer its 52-week high, VanEck Rare Earth/Strategic Metals nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Rare Earth/Strategic Metals for 50 Days and Tempus AI for 22 Days on average.
| REMX | TEM | |
|---|---|---|
Market Cap | $1.79B | $12.77B |
Volume | 1,233,740 | 8,980,490 |
Sector | Sector/Thematic | Broad Market / Factor |
52-Week High | $109.53 | $99.28 |
52-Week Low | $60.58 | $41.55 |
Typical Hold Time | 50 Days | 22 Days |
Enterprise Value | — | $13.40B |
Signals from Pluang's Aura AI — not financial advice
REMX (VanEck Rare Earth and Strategic Metals ETF) is trading at $61.88, down 2.99% with a bearish technical signal. The ETF faces selling pressure across moving averages and oscillators, though RSI readings below 23 suggest potential oversold conditions. Recent news highlights increased institutional interest from Bank of America while the rare earth sector navigates geopolitical tensions and U.S. supply chain developments.
The ETF's high volatility (~50% annualized) and China-heavy exposure present significant risks, though strategic importance of rare earth metals for defense and technology offers long-term thematic appeal. Current technical weakness contrasts with fundamental tailwinds from U.S. supply chain initiatives, creating a contested investment case requiring careful risk assessment.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite negative profitability. Recent FDA clearance for its ECG-MR AI product and 13 abstracts accepted for ESMO Congress 2026 highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist. The stock shows strong analyst support with a $72.60 consensus target and 64% buy ratings.
Outlook remains cautiously optimistic driven by AI healthcare adoption and data licensing growth, but high valuation multiples and sustained losses pose risks. Investor sentiment is positive amid recent insider selling and institutional interest, yet profitability challenges and competitive pressures require monitoring for long-term value creation.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →